Immix Biopharma reported a 95% complete response rate in interim data from the NEXICART-2 trial of NXC-201 for relapsed/refractory AL amyloidosis. The result is a strong clinical signal for the program and supports the company’s therapeutic pipeline. While materially positive for the stock, this is still interim trial data rather than a regulatory approval.
Immix Biopharma reported a 95% complete response rate in interim data from the NEXICART-2 trial of NXC-201 for relapsed/refractory AL amyloidosis. The result is a strong clinical signal for the program and supports the company’s therapeutic pipeline. While materially positive for the stock, this is still interim trial data rather than a regulatory approval.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.72
Ticker Sentiment
